Protective Role of Oxcarbazepine in Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
Multiple Sclerosis
Interventions
DRUG

Oxcarbazepine

Oxcarbazepine 150mg tablet, over encapsulated and back-filled with Microcrystalline Cellulose/Magnesium Stearate 1%.

DRUG

Placebo

Placebo in a matched capsule containing Microcrystalline Cellulose/Magnesium Stearate 1%.

Trial Locations (1)

E1 1BB

Barts Health NHS Trust, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Multiple Sclerosis Society

OTHER

collaborator

Novartis Pharmaceuticals

INDUSTRY

collaborator

Barts & The London NHS Trust

OTHER

collaborator

University College, London

OTHER

collaborator

Royal Free Hospital NHS Foundation Trust

OTHER

collaborator

Mid and South Essex NHS Foundation Trust

OTHER

collaborator

St George's Healthcare NHS Trust

OTHER

collaborator

Barnet and Chase Farm Hospitals NHS Trust

OTHER

lead

Queen Mary University of London

OTHER